Class II but not second class - prospects for the development of class II PI3K inhibitors

Simon John Mountford, Zhaohua Zheng, Krithika Sundaram, Ian Jennings, Justin Raymond Hamilton, Philip Thompson

Research output: Contribution to journalEditorialResearchpeer-review

8 Citations (Scopus)


The Class II PI3 kinases are emerging from the shadows of their Class I cousins. The data emerging from PIK3C2 genetic modification studies and from siRNA knockdown suggest important roles in physiology and pathology. With some well-studied Class I isoform inhibitors showing strong Class II activity and a wealth of crystallographic information available, the structural similarity of these isoforms to Class I provides both the opportunity and the challenge in design of selective pharmacological inhibitors.
Original languageEnglish
Pages (from-to)3 - 6
Number of pages4
JournalACS Medicinal Chemistry Letters
Issue number1
Publication statusPublished - 2015

Cite this